Your browser doesn't support javascript.
loading
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich, K; Körber, A; Mrowietz, U; Sticherling, M; Sieder, C; Früh, J; Bachhuber, T.
Affiliation
  • Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center, Hamburg, Germany.
  • Körber A; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Mrowietz U; Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
  • Sticherling M; Department of Dermatology, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Sieder C; Novartis Pharma GmbH, Nürnberg, Germany.
  • Früh J; Novartis Pharma AG, Basel, Switzerland.
  • Bachhuber T; Novartis Pharma AG, Basel, Switzerland.
Br J Dermatol ; 184(5): 849-856, 2021 05.
Article in En | MEDLINE | ID: mdl-32652528
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article